Evaluating Dentsply Sirona (XRAY) After a Recent Share Price Rebound and Ongoing Turnaround Efforts

Recent performance and setup

DENTSPLY SIRONA (XRAY) has quietly bounced about 8% over the past month, even as the stock remains down sharply this year, setting up an interesting reset in expectations for long term investors.

See our latest analysis for DENTSPLY SIRONA.

That recent 1 month share price return of about 8% is a welcome change of pace, but it comes against a much tougher backdrop, with the year to date share price return down sharply and multi year total shareholder returns still deeply negative. As a result, the latest bounce looks more like early repair than a full momentum shift.

If DENTSPLY SIRONA has you reassessing healthcare exposure, it might be worth scanning other healthcare stocks that currently pair interesting fundamentals with more consistent momentum.

With the shares still down nearly 40% year to date, yet trading at a steep intrinsic discount and below analyst targets, is DENTSPLY SIRONA now mispriced value, or is the market correctly bracing for muted future growth?

Most Popular Narrative Narrative: 12.1% Undervalued

With DENTSPLY SIRONA last closing at $11.39 versus a narrative fair value near $12.96, the most widely followed view implies modest upside from here.

Fair Value Estimate: Effectively unchanged at approximately $12.96 per share, indicating a stable intrinsic value assessment.

Discount Rate: Fallen slightly from about 10.57% to 10.21%, reflecting a modest reduction in perceived risk or required return.

Read the complete narrative.

Want to understand why a slow growing, currently unprofitable business still earns an upside valuation? The answer hides in its margin reset and long term earnings power. Curious which future profit profile and multiple this narrative quietly bakes in, and how that supports today’s target?

Result: Fair Value of $12.96 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, sustained U.S. sales weakness and ongoing leadership turnover could derail the turnaround, force deeper guidance cuts, and pressure today’s upside narrative.

Find out about the key risks to this DENTSPLY SIRONA narrative.

Build Your Own DENTSPLY SIRONA Narrative

If you see the story differently or want to stress test your own assumptions, you can build a fresh narrative in just a few minutes: Do it your way.

A great starting point for your DENTSPLY SIRONA research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.

Looking for more investment ideas?

Do not stop at one opportunity. Use the Simply Wall St Screener to pinpoint fresh stocks that match your strategy before the market wakes up to them.

• Capitalize on mispriced potential by targeting these 908 undervalued stocks based on cash flows that may offer solid cash flow upside before sentiment catches up.
• Ride powerful technology trends by focusing on these 26 AI penny stocks positioned to benefit from accelerating adoption of artificial intelligence.
• Strengthen your income stream by lining up these 13 dividend stocks with yields > 3% that can support long term, compounding returns.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com